Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline

Unusual Whales
2026.04.28 08:10
On April 28, 2026, in Hong Kong, Akeso, Inc. (9926.HK) revealed that ivonescimab, their groundbreaking PD-1/VEGF bispecific antibody, has obtained significant enhancements and advancements in various treatment settings. The company's innovative drug has received widespread recognition and improvements for both initial and subsequent treatment stages.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer